OncoMatch/Clinical Trials/NCT06389123
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
Official title: A Novel Molecularly Targeted Theranostic Approach Via the αvβ6 Integrin for the Detection and Treatment of Metastatic Carcinomas
Is NCT06389123 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. for metastatic cancer.
Treatment: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — metastatic disease
tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen (Androgen Deprivation allowed) as established by diagnostic imaging
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1000 cells/mm3; platelet count ≥ 100,000/mm3; hemoglobin ≥ 8 g/dl
Kidney function
creatinine ≤ 2 times uln
Liver function
ast, alt, alkaline phosphatase ≤ 5 times upper limit of normal (uln); total bilirubin ≤ 2 times uln
Cardiac function
no class 3 or 4 nyha congestive heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06389123 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify